창부도담탕의 다낭성 난소 증후군 치료 효과에 관한 동물 실험연구 고찰

키워드

참고문헌 (46)

1. Korean society of Obstetrics and Gynecology, "Obstetrics and Gynecology Guidelines and Summary", pp.505~ (2021), Koonja publishing
2. McCartney CR, "Polycystic Ovary Syndrome", N Engl J Med, 375(1), pp.54~64 (2016)
3. Hart R, "Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome", Best Pract Res Clin Obstet Gynaecol, 18(5), pp.671~683 (2004)
4. Gilbert EW, "Comorbidities and complications of polycystic ovary syndrome : an overview of systematic reviews", Clin Endocrinol, 89(6), pp.683~699 (2018)
5. Peck R, "Significant Risks of Oral Contraceptives(OCPs) : Why This Drug Class Should Not Be Included in a Preventive Care Mandate", Linacre Q, 79(1), pp.41~56 (2012)
6. Vause TDR, "Ovulation induction in polycystic ovary syndrome", J Obstet Gynaecol Can, 32(5), pp.495~502 (2010)
7. Hwang DS, "Korean Medicine for Women Infertility", J East-West Nurs Res, 28(2), pp.100~108 (2022)
8. The Society of Korean Medicine Obstetrics and Gynecology, "Oriental Obstetrics & Gynecology", pp.195~207 (2021), Euiseongdang
9. The Society of Korean Medicine Obstetrics and Gynecology, "Korean Medicine Gynecology Resident Treatment Manual (2nd volume)", pp.550~553 (2017), Euiseongdang
10. Pan A, "Study on the Effect of Cangfu Daotan Tang on Endocrine Hormones and the Expression of miRNA-16 and PDCD-4 in Obese PCOS Rats", Guiding J Tradit Chin Med Pharm, 30(4), pp.9~12 (2024)
11. Liu Y, "To investigate the mechanism of Cangfu Daotan Decoction in treating obese PCOS Rats based on lipid metabolism", Lishhizhen Med Mater Med Res, 34(1), pp.6~9 (2023)
12. Zhang Y, "Effect of Cangfu Daotan Decoction on ovarian cell proliferation and apoptosis in a rat model of obese polycystic ovary syndrome by regulation of PI3K", Akt signaling activit, 2023, pp.33(4), 297~302
13. Zhang Y, "The ameliorative effect of CangFu Daotan Decoction on polycystic ovary syndrome of rodent model is associated with m6A methylation and Wnt", β-catenin pathway, 2023, pp.39(1), 1~12
14. Pan A, "The study on the therapeutic mechanism of Cangfu Daotan Decoction for treating polycystic ovary syndrome in rats(苍附导痰汤对多囊卵巢综合征大鼠治疗机制的研究)", Zhong Yao Cai, 45(12), pp.3003~3006 (2022)
15. Wang C, "Effect of Cangfu Daotan Decoction on Ovarian Morphology and Follicular Development in Letrozole Induced Polycystic Ovary Syndrome Model Rats", Chin J Mod Appl Pharm, 39(20), pp.2593~2599 (2022)
16. Wu X, "Investigation of the Therapeutic Effect of Cangfu Daotan Decoction on Polycystic Ovary Syndrome Rats of Phlegm-damp Type Based on TLR-4", NF-κB Signaling Pathway, 2022, pp.33(3), 307~312
17. Yi W, "Effects of Cangfu Daotan Decoction on obese polycystic ovary syndrome and its mechanism", Steroids, 165, pp.108740~ (2021)
18. He M, "Effect of Cangfu Daotan Decoction on Ovarian Morphology and Androgen in Rats with Mifepristone-Induced Polycystic Ovary Syndrome", J Hunan Univ Chin Med, 38(8), pp.862~865 (2018)
19. Pan A, "The Effect of Cangfudaotan Tang on oatp3a1 Expression in Rats of Obese PCOS", Shizhen Guo Yi Guo Yao, 29(4), pp.817~820 (2018)
20. Pan A, "Effects of the Cangfu Daotan decoction on leptin, adiponectin level and insulin sensitivity index in fat rats with PCOS", Clin J Chin Med, 7(1), pp.4~6 (2015)
21. Wang Y, "Effect of CangFu DaoTan Decoction on Leptin, Adiponectin and TNF-α Levels of Polycystic Ovarian Syndrome Model Rats", Chin Arch Tradit Chin Med, 30(2), pp.418~420 (2012)
22. Yang SJ, "Effects of Changbu DodamTang on the Polycystic Ovaries Induced by Estradiol Valerate in Rats", J Korean Obstet Gyneco, 15(2), pp.1~11 (2002)
23. Carmina E, "Polycystic ovary syndrome(PCOS) : arguably the most common endocrinopathy is associated with significant morbidity in women", J Clin Endocrinol Metab, 84(6), pp.1897~1899 (1999)
24. Dumesic DA, "Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome", Endocr Rev, 36(5), pp.487~525 (2015)
25. Wang R, "The Rotterdam criteria for polycystic ovary syndrome : evidence-based criteria?", Hum Reprod, 32(2), pp.261~264 (2017)
26. Rotterdam ESHRE, "ASRM-Sponsored PCOS consensus workshop group", Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, 2004, pp.81(1), 19~25
27. Kathleen MH, "Update on PCOS : Consequences, Challenges, and Guiding Treatment", J Clin Endocrinol Metab, 106(3), pp.1071~1083 (2021)
28. Tamadon A, "How to choose the suitable animal model of polycystic ovary syndrome?", Tradit Med Mod Med, 1(2), pp.95~113 (2018)
29. Kauffman AS, "A novel letrozole model recapitulates both the reproductive and metabolic phenotypes of polycystic ovary syndrome in female mice", Biol Reprod, 93(3), pp.1~12 (2015)
30. Lord JM, "Metformin in polycystic ovary syndrome : systematic review and meta-analysis", BMJ, 327(7421), pp.951~953 (2003)
31. National Korean Medicine University Herbal Medicine Textbook Compilation Committee, "Bonchohag", pp.216~635 (2020), Young Lim Co
32. Sin JY, "Analysis of Bangyaghabpyeon", pp.319~ (1994), Seongbosa
33. Das M, "Granulosa cell survival and proliferation are altered in polycystic ovary syndrome", J Clin Endocrinol Metab, 93(3), pp.881~887 (2008)
34. Dumitrescu R, "The polycystic ovary syndrome : an update on metabolic and hormonal mechanisms", J Med Life, 8(2), pp.142~145 (2015)
35. Chen J, "The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome", J Ovarian Res, 8, pp.1~6 (2015)
36. Gambineri A, "Obesity and the polycystic ovary syndrome", Int J Obes, 26, pp.883~896 (2002)
37. Diamanti-Kandarakis E, "Insulin resistance and the polycystic ovary syndrome revisited : an update on mechanisms and implications", Endocr Rev, 33(6), pp.981~1030 (2012)
38. Wild RA, "Dyslipidemia in PCOS", Steroids, 77(4), pp.295~299 (2012)
39. Gonzalez F, "Inflammation in polycystic ovary syndrome : underpinning of insulin resistance and ovarian dysfunction", Steroids, 77(4), pp.300~305 (2012)
40. Rudnicka E, "Chronic low grade inflammation in pathogenesis of PCOS", Int J Mol Sci, 22(7), pp.3789~ (2021)
41. Tsai YR, "Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome", Cells, 12(17), pp.1~26 (2023)
42. Gong Y, "Growth hormone activates PI3K", Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome, 2020, pp.18(1), 12~
43. Wu XQ, "The WNT", β-catenin signaling pathway may be involved in granulosa cell apoptosis from patients with PCOS in North China, 2017, pp.46(1), 93~99
44. Fu X, "MicroRNA-16 promotes ovarian granulosa cell proliferation and suppresses apoptosis through targeting PDCD4 in polycystic ovarian syndrome", Cell Physiol Biochem, 48(2), pp.670~682 (2018)
45. Pan J, "Research progress of PCNA in reproductive system diseases", Evid Based Complement Alternat Med, 2021(1), pp.1~8 (2021)
46. Hagenbuch B, "Xenobiotic transporters of the human organic anion transporting polypeptides(OATP)family", Xenobiotica, 38(7-8), pp.778~801 (2008)

관련 논문AI추천